


selected from N or CH; wherein there are no more than 3 nitrogen ring atoms in ring B and ring B does not contain 3 nitrogen ring atoms at 3 contiguous positions;

T⁶, T⁷, and T⁸ are each independently selected from N and CR⁴;

EE is -COOH;



each R¹ is independently selected from H, halogen, -CN, OH, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, NR^{5'}R^{6'}, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, or C₂-C₆ alkynyl represented by R¹ is optionally substituted with one or more groups selected from halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, and saturated or partially saturated C₃-C₆ cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃); and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R¹ or in the group represented by R¹ is optionally substituted with one or more groups selected from halogen, oxo (as appropriate), CN, OH, C₁-C₃ alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH₃), and C₁-C₃ alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH₃), and NR^{5'}R^{6'}.

each R² is independently selected from halogen, -CN, OH, C₁-C₂ alkyl, C₁-C₂ haloalkyl, and C₁-C₂ alkoxy;

each R³ is independently selected from halogen, CN, OH, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, and NR^{5'}R^{6'};

each R⁴ is independently selected from H, F, Cl, methyl, and methoxy;

R^{5'} and R^{6'} are each independently selected from hydrogen and C₁-C₆ alkyl;


m is an integer selected from 0, 1, 2, 3, and 4;

n is an integer selected from 0, 1, 2, 3, and 4

o is an integer selected from 0, 1, 2, 3, and 4.


CLAIMS

1. A compound represented by structural formula (III):



or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein:

- 5 X^1 , X^2 , X^3 , X^4 , and X^5 are each independently selected from N and CH; wherein no more than three of X^1 , X^2 , X^3 , X^4 , and X^5 are N and wherein ring A does not contain 3 nitrogen ring atoms at 3 contiguous positions;
- ring B is 6-membered heteroaryl or phenyl, wherein Y^1 , Y^3 , Y^4 , and Y^5 are each independently selected from N or CH; wherein there are no more than 3 nitrogen ring atoms in ring B and ring B does not contain 3 nitrogen ring atoms at 3 contiguous positions;
- 10 T^6 , T^7 , and T^8 are each independently selected from N and CR^4 ;
- EE is $-COOH$;



- each R^1 is independently selected from H, halogen, $-CN$, OH , C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NR^5R^6 , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, or C_2-C_6 alkynyl represented by R^1 is optionally substituted with one or more groups selected from halogen, oxo, CN , CF_3 , OH , OCH_3 , OCH_2CH_3 , and saturated or partially saturated C_3-C_6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN , CF_3 , OH , OCH_3 , OCH_2CH_3); and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R^1 or in the group represented by R^1 is optionally substituted with one or more groups selected from halogen, oxo (as appropriate), CN , OH , C_1-C_3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH , and OCH_3), and C_1-C_3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH , and OCH_3), and NR^5R^6 .
- 25

each R^2 is independently selected from halogen, $-CN$, OH , C_1-C_2 alkyl, C_1-C_2 haloalkyl, and C_1-C_2 alkoxy;

each R^3 is independently selected from halogen, CN, OH, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy, and $NR^{5'}R^{6'}$;

each R^4 is independently selected from H, F, Cl, methyl, and methoxy;

$R^{5'}$ and $R^{6'}$ are each independently selected from hydrogen and C_1 - C_6 alkyl;

5 m is an integer selected from 0, 1, 2, 3, and 4;


n is an integer selected from 0, 1, 2, 3, and 4

o is an integer selected from 0, 1, 2, 3, and 4.

2. The compound according to claim 1, or a pharmaceutically acceptable salt, or stereoisomer

10


thereof, wherein



wherein n is an integer selected from 0, 1, 2, and 3 as appropriate.

15


3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein ring A is



each R^1 is independently selected from halogen, OH, CN, CF_3 , C_1 - C_2 alkyl, C_1 - C_2 haloalkyl, C_1 - C_2 alkoxy, $-NH_2$, $-NHC_1$ - C_2 alkyl, $-N(C_1$ - C_2 alkyl)₂, and C_2 - C_4 alkynyl optionally substituted with cyclopropane; and m is an integer selected from 0, 1, and 2.


20

4. The compound according to claim 2 or 3, or a pharmaceutically acceptable salt, or



5


5. The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein ring A is



each R¹ is independently selected from halogen, OH, CN, C₁-C₂ alkyl, C₁-C₂ haloalkyl, C₁-C₂ alkoxy, and C₂-C₄ alkynyl; and m is an integer selected from 0, 1, and 2.

10

6. The compound according to any one of claims 2-5, or a pharmaceutically acceptable salt, or




15

7. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein each R² is independently selected from halogen (e.g., F); and n is an integer selected from 0, 1, and 2.

20


8. The compound according to any one of claims 1-7, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein each R³ is F, Cl or CH₃; and o is 0, 1, or 2.

199. The compound according to any one of claims 1-8, or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein ring A is



5


10. The compound according to any one of claims 1-9, or a pharmaceutically acceptable salt or



stereoisomer thereof, wherein


is

- 10 11. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt or



stereoisomer thereof, wherein


12. The compound according to any one of claims 1-11, or a pharmaceutically acceptable salt or



stereoisomer thereof, wherein ring A is

15

13. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt, or




stereoisomer thereof, wherein ring A is


14. The compound according to any one of claims 1-13, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R³ is F or CH₃; and o is 2.

20

15. The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is selected from the group consisting of


5






5


10



16. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following structure:



17. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following structure:



18. A pharmaceutical composition comprising the compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
19. A compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof, for use in treating cardiometabolic and associated diseases, wherein the disease is type 1 diabetes, type 2 diabetes mellitus, obesity, hyperglycemia, non-alcoholic steatohepatitis, Alzheimer's Disease, Parkinson's Disease, ulcerative colitis, or nonalcoholic fatty liver disease.
20. Use of a therapeutically effective amount of a compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for of treating a subject in need of with cardiometabolic and associated diseases, wherein the disease is type 1 diabetes, type 2 diabetes mellitus, obesity, hyperglycemia, non-alcoholic steatohepatitis, Alzheimer's Disease, Parkinson's Disease, ulcerative colitis, or nonalcoholic fatty liver disease.